New advances in the management of acute coronary syndromes: 3. The role of catheter-based procedures

CMAJ. Canadian Medical Association Journal

Volumn 166, Issue 1, 2002, Pages 51-61

  Buller, Christopher E ^a   Carere, Ronald G ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; METOPROLOL; RAMIPRIL; SIMVASTATIN; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ACUTE HEART FAILURE; ANGIOPLASTY; CLINICAL FEATURE; CLINICAL TRIAL; CONVALESCENCE; CORONARY STENT; DISEASE COURSE; DRUG INDUCED DISEASE; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; META ANALYSIS; RESTENOSIS; REVIEW; ST SEGMENT ELEVATION; TECHNIQUE; TREATMENT OUTCOME;

EID: 0036146888     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Improved clinical outcome after widespread use of coronary-artery stenting in Canada
2. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
3. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
4. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): A randomised trial
5. Primary stenting versus balloon angioplasty in occluded coronary arteries: The Total Occlusion Study of Canada (TOSCA)
6. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation
7. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One-year outcome in the EPILOG trial (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade)
8. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
9. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
10. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
11. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization
12. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
13. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
14. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
15. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction
16. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review
17. Coronary angioplasty with or without stent implantation for acute myocardial infarction
18. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction
19. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction
20. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction
21. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
22. CADILLAC trial results: Controlled abciximab and device investigation to lower late angioplasty complications
23. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": One-year results from a nationwide French survey
24. Rescue angioplasty after failed thrombolysis: Technical and clinical outcomes in a large thrombolysis trial
25. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction
26. One-year survival following early revascularization for cardiogenic shock
27. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in acute myocardial infarction
28. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction
29. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy
30. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial
31. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
32. New advances in the management of acute coronary syndromes: 1. Matching treatment to risk